Search bioRxiv⌕ Search

Biology subjects

Schechtman, D.

Publications and source records attributed to Schechtman, D..

4 recordsLinked to original sources

Subtype-Resolved Pain-Signaling Architectures Reveal Conserved Drug-Target Interaction Networks in DRG Nociceptors

Pain management has been challenging and a major obstacle lies in the limited translational success between preclinical studies, often based on rodent models and evoked nociception behavioral assays, whose validity is often questioned. The dorsal root ganglia (DRG) contains diverse nociceptor subtypes that serve as the primary afferent pathways for detecting painful stimuli and analgesics often target proteins expressed in nociceptors. This makes the distinct protein repertoires and molecular interactors within nociceptor subtypes a key focus for understanding which molecular players drive pain processing and how they may be therapeutically targeted. The confirmation of cross-species conservation of pain-related signaling pathways, mediated by nociceptors, could help to elucidate the molecular mechanisms by which the drugs act across species. In this context, we constructed and compared experimentally-validated protein-protein interaction (PPI) networks based on drug targets and their direct binding partners for nociceptor subtypes supported by single-nuclei transcriptome data from mouse and human DRGs. We found that overall gene expression is more conserved across mice than in human nociceptor subtypes, indicating a higher degree of molecular specialization of human nociceptors. Overall signaling network analyses revealed subtype- and species-specific conservation related to pain signaling, with some particularities, in which key drug targets mediate broader cellular processes beyond pain signaling and neuronal depolarization. Altogether, this resource may help to further understand the molecular mechanisms of specific drug targeting, and the proposed workflow can be used to identify and prioritize pain-related pathways in the DRG, advancing target identification and translational medicine.

cell biology↗

Temporal regulation of TRP channels during partial sciatic nerve ligation is modulated by PLCγ in male mice

Neuropathic pain is a debilitating condition afflicting millions worldwide, still lacking a proper and effective treatment. Understanding the underlying mechanisms that lead to neuropathic pain may lead to the discovery of new targets. Previously, we found that PLC{square} is a key player in mechanical hypersensitivity triggered by either capsaicin or complete Freunds adjuvant induced inflammation. Here, we investigated the role of PLC{gamma} in neuropathic pain using a partial sciatic nerve ligation (PSNL) injury model in male mice and a peptide inhibitor of PLC{gamma} activation (TAT-pQYP) injected at different time points after injury. Mechanical hypersensitivity was reversed by TAT-pQYP at 7, 14, and 28 days post-injury (dpi). Furthermore, both TAT-pQYP and the TRPA1 inhibitor HC-030031, but not the TRPV1 inhibitor capsazepine, were able to reverse mechanical hypersensitivity at 14 dpi. In contrast, all three treatments significantly improved the mechanical threshold at 28 dpi. After a challenge with TRPV1 agonist capsaicin at 14 dpi, TAT-pQYP treated animals exhibited increased sensitivity. We also found decreased TRPV1 mRNA levels in the DRG of PSNL animals at 14 dpi that returned to baseline at 28 dpi. TAT-pQYP treatment normalized TRPV1 expression to sham levels at 14 days. Conversely, TRPA1 mRNA expression increased at 14 days and returned to baseline at 28 days, while TAT-pQYP reduced TRPA1 expression at 14 days. At this same time point, injection of a pan-PLC (U73122), or Trk (GNF-5837) inhibitor reduced mechanical hypersensitivity and decreased Trpa1 expression, whereas only PLC{square} inhibition by TAT-pQYP or Trk inhibition restored Trpv1 levels to Sham values. These findings indicate that PLC{gamma}, and Trk signaling are important for expression of Trpa1 and activity of Trpv1. Taken together, our results show that dynamic changes in Trpv1 expression in the PSNL model account for differential sensitivity to TRPV1 inhibition and suggest that clinically relevant pharmacological inhibitors targeting ion channels may vary in efficacy depending on the temporal regulation of expression during neuropathic pain development. Finally, we show that TAT-pQYP is able to reverse mechanical hypersensitivity arising from neuropathic pain, adding evidence that PLC{gamma} is a promising target to be explored for neuropathic pain management. Significance statementWe show that the efficacy of inhibiting TRPV1 or TRPA1 on neuropathic pain in a partial sciatic nerve ligation model and that pain mitigation depends on the dynamic changes of channel expression post-injury, in the dorsal root ganglion, emphasizing that temporal regulation of drug targets should be taken into account when choosing therapeutic strategies for pain treatment. Notably, we identify PLC{gamma} as a promising therapeutic target, as its inhibition with TAT-pQYP reverses mechanical hypersensitivity during different stages of injury progression by modulating expression and activity of TRP channels.

biochemistry↗

Functional roles of neural aPKCs in mouse brain development and survival

Conserved protein complexes establish and maintain cell polarity. In turn, cell polarity is indispensable for fundamental developmental processes such as asymmetric division of stem cells and establishment of subcellular membrane polarization during cell differentiation. There are three well characterized polarity complexes. Atypical Protein Kinase C (aPKC) is a conserved constituent of the PAR complex that phosphorylates not only substrates within this complex, but also in the other polarity complexes. Outside of the polarity complex, aPKC regulates a myriad of cellular processes such as migration, metabolism, and survival. In mammals, two paralogs, Prkci and Prkcz, form the aPKC subfamily. Here, we characterized the expression of the Prkci and Prkcz paralogs, including a variant transcript of Prkcz, in the mouse brain and specific cells of the neural lineage. We generated a series of mice with individual and collective ablation of the two aPKC paralogs in neural stem cells, new-born neurons, astrocytes and NG2+ cells, as well as a mouse expressing kinase-inactive PRKCI in neural progenitors. We examine the effects of loss of aPKC paralogs or its kinase activity on gross brain development and organismal viability. Our results identify a critical window in neural progenitor differentiation wherein aPKC function is indispensable for neurodevelopment. Beyond this period, the ablation of even both aPKCs is characterized by a conspicuous absence of anticipated drastic effects. The genetic models developed might prove useful for further interrogating aPKC function in neurodevelopment and neuronal function or to reveal the role of polarity complex function in neurons, astrocytes and oligodendrocytes during stress, injuries or diseases.

developmental biology↗

The SARS-CoV-2 Nsp3 macrodomain reverses PARP9/DTX3L-dependent ADP-ribosylation induced by interferon signalling

SARS-CoV-2 non-structural protein 3 (Nsp3) contains a macrodomain that is essential for virus replication and is thus an attractive target for drug development. This macrodomain is thought to counteract the host interferon (IFN) response, an important antiviral signalling cascade, via the removal of ADP-ribose modifications catalysed by host poly(ADP-ribose) polymerases (PARPs). Here, we show that activation of the IFN response induces ADP-ribosylation of host proteins and that ectopic expression of the SARS-CoV-2 Nsp3 macrodomain reverses this modification in human cells. We further demonstrate that this can be used to screen for cell-active macrodomain inhibitors without the requirement for BSL-3 facilities. This IFN-induced ADP-ribosylation is dependent on the PARP9/DTX3L heterodimer, but surprisingly the expression of Nsp3 macrodomain or PARP9/DTX3L deletion do not impair STAT1 phosphorylation or the induction of IFN-responsive genes. Our results suggest that PARP9/DTX3L-dependent ADP-ribosylation is a downstream effector of the host IFN response and that the cellular function of the SARS-CoV-2 Nsp3 macrodomain is to hydrolyse this end product of IFN signalling, and not to suppress the IFN response itself.

molecular biology↗